The report highlights Revance's commitment to ESG principles and its progress in areas such as diversity and inclusion, employee safety, and environmental sustainability. The report also outlines the company's strategic partnerships and its focus on innovation and access to medicines. The report is guided by the Biotechnology & Pharmaceuticals guidelines from the Sustainability Accounting Standards Board (SASB) and the results of Revance's ESG materiality assessment.
Issuing Company Revance Therapeutics Inc.
Report Type Sustainability Report
Report Language EN
Report Filesize 6.56 MB
No. of Pages 57 pages
Reporting periodJanuary 1, 2020-December 31, 2020
Report EditionUnknown
Assurance Provider Unknown
Reporting Standards SASB
Materiality Assessmenttrue